查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1415416

真菌感染疾病診斷市場：按類型、診斷方法、最終用戶分類 - 全球預測 2024-2030

Fungal Infections Diagnosis Market by Type, Diagnostic Method, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

真菌感染疾病診斷市場規模預計2023年為20.9億美元，2024年達22.3億美元，預計2030年將達到33.5億美元，複合年成長率為6.96%。

真菌感染疾病診斷的全球市場

主要市場統計
基準年[2023] 20.9億美元
預測年份 [2024] 22.3億美元
預測年份 [2030] 33.5億美元
複合年成長率（%） 6.96%
真菌感染診斷市場-IMG1

真菌感染疾病（真菌疾病）是指由真菌（酵母菌或黴菌）引起的感染疾病或疾病。真菌感染疾病最常見於皮膚和指甲，但真菌也會引起口腔、喉嚨、肺部和泌尿道感染疾病。真菌感染疾病包括足癬、香港腳、趾甲真菌、酵母菌感染疾病和掌蹠膿皰病。真菌感染疾病的診斷主要依賴臨床檢體鏡檢、組織病理學檢查、培養、X光檢查、MRI檢查、CT影像檢查等方法。世界各地真菌感染疾病的增加急劇增加了對有效疾病檢測技術的需求。此外，政府努力提高人們對真菌感染疾病管理的認知，並努力擴大醫療機構的可近性，從而提高了真菌感染疾病診斷的採用率。然而，真菌感染疾病分子和遺傳學診斷的複雜性以及熟練醫療和臨床人員的缺乏正在阻礙真菌感染疾病診斷解決方案的成長。此外，不準確或不一致的診斷結果以及產品核可的嚴格規定也給真菌感染疾病診斷設備、解決方案和服務帶來了挑戰。然而，主要企業正在迅速增加研發投資，以提高診斷技術的功效和準確性。成像技術的進步正在增強遠距離診斷的數位解決方案，而快速診斷技術中人工智慧的引入則提供了成長機會。

區域洞察

以美國和加拿大為中心的美洲地區，由於大眾對真菌感染疾病的認知不斷提高，已成為真菌感染疾病診斷工具的成熟地區。美洲的特點是擁有強大的研究機構和醫療基礎設施，這有助於及時、準確地診斷各種真菌感染疾病。 PCR 和次世代定序儀等診斷技術的進步正在加速美洲的診斷過程、提高準確性並減少潛在的致命風險。在歐洲，真菌感染疾病的盛行率正在顯著增加，主要是在老年人口和免疫抑制的人群中。對真菌感染疾病的認知不斷提高，增加了對有效診斷工具的需求。歐洲地區的旅行和移民正在增加，導致各種真菌病原體的引入和傳播。因此，醫療保健專業人員正在採用創新的真菌感染疾病診斷方法來有效管理這些高風險環境中潛在的疫情爆發。該地區的特點是研發投資龐大，新興企業數量不斷增加。亞太地區（APAC）真菌感染疾病的發生率正在急劇增加，這主要是由於人口密度的增加和有利於真菌生長的氣候條件。以中國、日本和印度為中心的亞太地區由於醫療成本急劇上升和患者意識增強而具有巨大潛力。

FPNV定位矩陣

FPNV 定位矩陣對於評估真菌感染疾病診斷市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對真菌感染疾病診斷市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-真菌感染疾病診斷市場的市場規模和預測是多少？

2-在真菌感染疾病診斷市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-真菌感染疾病診斷市場的技術趨勢和法律規範是什麼？

4-真菌感染疾病診斷市場主要供應商的市場佔有率是多少？

5-進入真菌感染疾病診斷市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 真菌感染疾病的流行和有效診斷方法的需求
      • 政府提高真菌感染疾病管理意識的舉措
      • 真菌感染疾病測試系列成功核准
    • 抑制因素
      • 分子和遺傳真菌感染疾病診斷的複雜性
    • 機會
      • 分子和照護端診斷技術的進步
      • 遠距皮膚病學在檢測和診斷真菌感染疾病方面的潛力
    • 任務
      • 與診斷方法不準確相關的局限性
  • 市場區隔分析
    • 類型：由於患者免疫力減弱，導致機會性真菌感染疾病的發生率增加
    • 診斷方法：細胞和分子生物學的進步導致採用分子診斷方法來檢測感染疾病。
    • 最終用戶：不斷擴大的醫療保健成本導致醫院真菌感染疾病診斷的成長和重要性
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章真菌感染疾病診斷市場：按類型

  • 地方性真菌感染疾病
  • 機會性真菌感染疾病
  • 皮下真菌感染疾病
  • 表層真菌感染疾病
  • 全身性真菌感染疾病

第7章依診斷方法分類的真菌感染疾病診斷市場

  • 抗原測試
  • 皮膚科檢查
  • 組織病理學
  • 微生物培養
  • 分子診斷
  • 血清學

第8章真菌感染疾病診斷市場：依最終用戶分類

  • 醫院
  • 照護端設置
  • 調查機構
  • 專科診所

第9章北美和南美真菌感染疾病診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區真菌感染疾病診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲真菌感染疾病診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析
    • 新產品發布和功能增強

第13章競爭產品組合

  • 主要公司簡介
    • Abbott Laboratories
    • Alexion Pharmaceuticals, Inc.
    • Amgen Inc.
    • Associates of Cape COD, Inc. by Seikagaku Group company
    • Astellas Pharma Inc.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • BioMerieux SA
    • Bruker Corporation
    • Danaher Corporation
    • Eli Lilly and Company
    • ELITech Group
    • Eurofins Viracor, LLC
    • F. Hoffmann-La Roche AG
    • Hologic, Inc.
    • Immununexpress Inc.
    • IMMY
    • InBios International, Inc.
    • Laboratory Corporation of America Holdings
    • Merck KGaA
    • Norgen Biotek Corp.
    • PerkinElmer, Inc.
    • Polysciences, Inc.
    • Qiagen NV
    • Siemens Healthineers
    • Takeda Pharmaceutical Company Limited
    • Thermo Fisher Scientific Inc.
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-346757DFA1EA

[194 Pages Report] The Fungal Infections Diagnosis Market size was estimated at USD 2.09 billion in 2023 and expected to reach USD 2.23 billion in 2024, at a CAGR 6.96% to reach USD 3.35 billion by 2030.

Global Fungal Infections Diagnosis Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.23 billion
Forecast Year [2030] USD 3.35 billion
CAGR (%) 6.96%
Fungal Infections Diagnosis Market - IMG1

Fungal infections, or mycosis, refer to infections or diseases caused by a fungus species (yeast or mold). Fungal infections are most commonly observed on the skin or nails, but fungi can also cause infections in the mouth, throat, lungs, and urinary tract. Fungal infections come in different forms, such as ringworm athlete's foot, toenail fungus, yeast infections, and jock itch. Diagnosis of fungal infection primarily relies on methodologies such as microscopic examination of clinical samples, histopathology, culture, X-rays, MRI, or CT imaging. The rising incidences of fungal infections across the world have led to a surge in demand for effective disease detection technologies. Furthermore, government initiatives promoting awareness of fungal infection management and efforts to expand access to healthcare facilities have led to rising adoption of fungal infection diagnosis. However, the complexity of molecular and genetic fungal infection diagnosis and the lack of skilled medical and clinical personnel impeded the growth of fungal infection diagnosis solutions. Additionally, inaccurate or inconsistent diagnosis results and stringent regulations pertaining to product approval also pose challenges for fungal infection diagnosis devices, solutions, and services. However, major players are rapidly expanding investments in R&D initiatives to improve the capabilities and accuracy of diagnosis technologies. Advances in imaging technologies enhanced digital solutions for remote diagnosis and the introduction of artificial intelligence in rapid diagnostic techniques present opportunities for growth.

Regional Insights

The Americas, specifically the US and Canada, present a mature region for fungal infections diagnostic tools, attributable to the increased public consciousness about fungal infections. Americas is characterized by the presence of robust research institutions and medical infrastructure, contributing to the timely and accurate diagnosis of various fungal infections. The technological advancements in diagnostic techniques, including PCR and next-generation sequencing, have accelerated the diagnosis process, improved accuracy, and reduced the potential risk of fatality in the Americas region. In Europe, the spread of fungal infections shows a significant increase, mostly attributed to the elderly population and those with immunosuppressive conditions. There is a rising demand for effective diagnostic tools driven by increased awareness about fungal infections. European region exhibits a rise in travel and migration, which contributes to the introduction and spread of various fungal pathogens. Medical practitioners, therefore, adopt innovative fungal infection diagnostics to manage the potential outbreaks in this high-risk environment effectively. Significant investments in R&D and a growing number of start-ups characterize this region. Asia-Pacific (APAC) region is witnessing an upsurge in the incidence of fungal infections, primarily due to escalating population density and climatic conditions that favor fungal growth. The APAC region, chiefly China, Japan, and India, shows immense potential due to escalating healthcare expenditure and a surge in patient awareness.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Fungal Infections Diagnosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Fungal Infections Diagnosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Fungal Infections Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alexion Pharmaceuticals, Inc., Amgen Inc., Associates of Cape COD, Inc. by Seikagaku Group company, Astellas Pharma Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Bruker Corporation, Danaher Corporation, Eli Lilly and Company, ELITech Group, Eurofins Viracor, LLC, F. Hoffmann-La Roche AG, Hologic, Inc., Immununexpress Inc., IMMY, InBios International, Inc., Laboratory Corporation of America Holdings, Merck KGaA, Norgen Biotek Corp., PerkinElmer, Inc., Polysciences, Inc., Qiagen N.V., Siemens Healthineers, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Fungal Infections Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Endemic Fungal Infections
    • Opportunistic Fungal Infections
    • Subcutaneous Fungal Infections
    • Superficial Fungal Infections
    • Systemic Fungal Infections
  • Diagnostic Method
    • Antigen Testing
    • Dermatological Examination
    • Histopathology
    • Microbiological Culture
    • Molecular Diagnostics
    • Serology
  • End-User
    • Hospitals
    • Point-of-Care Settings
    • Research Institutions
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Fungal Infections Diagnosis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Fungal Infections Diagnosis Market?

3. What are the technology trends and regulatory frameworks in the Fungal Infections Diagnosis Market?

4. What is the market share of the leading vendors in the Fungal Infections Diagnosis Market?

5. Which modes and strategic moves are suitable for entering the Fungal Infections Diagnosis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Fungal Infections Diagnosis Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of fungal infections and need for effective diagnosis methods
      • 5.1.1.2. Government initiatives promoting awareness of fungal infection management
      • 5.1.1.3. Favorable approvals for fungal infection test series
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of molecular and genetic fungal infection diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in molecular and point-of-care diagnosis technologies
      • 5.1.3.2. Potential of teledermatology in fungal infection detection and diagnosis
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations associated with the inaccuracy of the diagnostic methods
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing incidences of opportunistic fungal infections due to weakened immune system in patients
    • 5.2.2. Diagnostic Method: Advancements in cellular and molecular biology leading to the adoption of molecular diagnostics for infection detection
    • 5.2.3. End-user: Expanding healthcare expenditure leading to growth and significance of hospitals for fungal infection diagnosis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Fungal Infections Diagnosis Market, by Type

  • 6.1. Introduction
  • 6.2. Endemic Fungal Infections
  • 6.3. Opportunistic Fungal Infections
  • 6.4. Subcutaneous Fungal Infections
  • 6.5. Superficial Fungal Infections
  • 6.6. Systemic Fungal Infections

7. Fungal Infections Diagnosis Market, by Diagnostic Method

  • 7.1. Introduction
  • 7.2. Antigen Testing
  • 7.3. Dermatological Examination
  • 7.4. Histopathology
  • 7.5. Microbiological Culture
  • 7.6. Molecular Diagnostics
  • 7.7. Serology

8. Fungal Infections Diagnosis Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Point-of-Care Settings
  • 8.4. Research Institutions
  • 8.5. Specialty Clinics

9. Americas Fungal Infections Diagnosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Fungal Infections Diagnosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Fungal Infections Diagnosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. New Product Launch & Enhancement
      • 12.3.1.1. University of Minnesota Research Team Successfully Tests New Antifungal Therapy For Fungal Meningitis
      • 12.3.1.2. Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use
      • 12.3.1.3. University of Arizona Researchers to Help Track Deadly Fungus in Arizona Wastewater

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. Alexion Pharmaceuticals, Inc.
    • 13.1.3. Amgen Inc.
    • 13.1.4. Associates of Cape COD, Inc. by Seikagaku Group company
    • 13.1.5. Astellas Pharma Inc.
    • 13.1.6. Becton, Dickinson and Company
    • 13.1.7. Bio-Rad Laboratories, Inc.
    • 13.1.8. BioMerieux SA
    • 13.1.9. Bruker Corporation
    • 13.1.10. Danaher Corporation
    • 13.1.11. Eli Lilly and Company
    • 13.1.12. ELITech Group
    • 13.1.13. Eurofins Viracor, LLC
    • 13.1.14. F. Hoffmann-La Roche AG
    • 13.1.15. Hologic, Inc.
    • 13.1.16. Immununexpress Inc.
    • 13.1.17. IMMY
    • 13.1.18. InBios International, Inc.
    • 13.1.19. Laboratory Corporation of America Holdings
    • 13.1.20. Merck KGaA
    • 13.1.21. Norgen Biotek Corp.
    • 13.1.22. PerkinElmer, Inc.
    • 13.1.23. Polysciences, Inc.
    • 13.1.24. Qiagen N.V.
    • 13.1.25. Siemens Healthineers
    • 13.1.26. Takeda Pharmaceutical Company Limited
    • 13.1.27. Thermo Fisher Scientific Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. FUNGAL INFECTIONS DIAGNOSIS MARKET DYNAMICS
  • FIGURE 7. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2030 (%)
  • FIGURE 10. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SYSTEMIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 12. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOLOGICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 151. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. FUNGAL INFECTIONS DIAGNOSIS MARKET LICENSE & PRICING